Pharmacokinetics of combined release formulations of a γ-hydroxybutyric acid derivative
Pharmaceutical compositions comprising an immediate release component comprising 4-((L-valyl)oxy)butanoic acid and a modified release component comprising 4-((L-valyl)oxy)butanoic acid and the pharmacokinetics of 4-((L-valyl)oxy)butanoic acid and γ-hydroxybutyrate following oral administration of the pharmaceutical compositions is disclosed.
1. A pharmaceutical composition comprising:
an immediate release component, wherein the immediate release component comprises from 2 g of γ-((L-valyl)oxy)butanoic acid to 7 g of γ-((L-valyl)oxy)butanoic acid; and
a modified release component, wherein the modified release component comprises from 7 g of γ-((L-valyl)oxy)butanoic acid to 15 g of γ-((L-valyl)oxy)butanoic acid.
2. The pharmaceutical composition of claim 1 , wherein
the immediate release component comprises from 10 wt % to 50 wt % of 4-((L-valyl)oxy)butanoic acid; and
the modified release component comprises from 50 wt % to 90 wt % of 4-((L-valyl)oxy)butanoic acid,
wherein wt % is based on the total weight of 4-((L-valyl)oxy)butanoic acid in the pharmaceutical composition.
3. The pharmaceutical composition of claim 1 , wherein
the immediate release component comprises a plurality of immediate release microparticles; and
the immediate release microparticles comprise greater than 90 wt % of 4-((L-valyl)oxy)butanoic acid, wherein wt % is based on the total weight of the immediate release microparticles.
4. The pharmaceutical composition of claim 1 , wherein
the modified release component comprises modified release microparticles;
the modified release microparticles comprise a core and a modified release coating surrounding the core; and
the core comprises greater than 90 wt % of 4-((L-valyl)oxy)butanoic acid, wherein wt % is based on the total weight of the core.
5. The pharmaceutical composition of claim 1 prepared by adding to water the immediate release component and the modified release component.
6. The pharmaceutical composition of claim 1 , wherein
the immediate release component comprises a plurality of immediate release microparticles;
the immediate release microparticles comprise:
from 98 wt % to 99 wt % of γ-((L-valyl)oxy)butanoic acid;
from 0.5 wt % to 1.5 wt % of a flow control agent; and
from 0.25 wt % to 0.75 wt % of a binder, wherein,
wt % is based on the total weight of the immediate release microparticles.
7. The pharmaceutical composition of claim 6 , wherein
the flow control agent comprises colloidal silicon dioxide; and
the binder comprises hydroxypropyl cellulose.
8. The pharmaceutical composition of claim 4 , wherein
the core of the modified release microparticles comprises
from 98 wt % to 99 wt % of γ-((L-valyl)oxy)butanoic acid;
from 0.5 wt % to 1.5 wt % of a flow control agent; and
from 0.25 wt % to 0.75 wt % of a binder, wherein,
wt % is based on the total weight of the core; and
the modified release coating comprises:
from 2 wt % to 12 wt % of a plasticizer;
from 65 wt % to 80 wt % of a water-insoluble polymer;
from 2 wt % to 6 wt % of a water-soluble polymer; and
from 12 wt % to 18 wt % of an antistatic agent, wherein,
wt % is based on the total weight of the modified release coating.
9. The pharmaceutical composition of claim 8 , wherein the modified release microparticles comprise from 10% wg to 40% wg of the modified release coating, wherein % wg refers to the weight of the modified release coating based on the weight of the core.
10. The pharmaceutical composition of claim 8 , wherein
the flow control agent comprises colloidal silicon dioxide;
the binder comprises hydroxypropyl cellulose;
the plasticizer comprises dibutyl sebacate;
the water-insoluble polymer comprises ethyl cellulose;
the water-soluble polymer comprises hydroxypropyl cellulose; and
the antistatic agent comprises magnesium silicate.
11. The pharmaceutical composition of claim 8 , wherein the modified release microparticles have an average particle diameter from 150 μm to 350 μm, wherein the average particle diameter is determined using laser diffraction or sieve analysis.
12. The pharmaceutical composition of claim 8 , wherein
the immediate release component comprises from 4 g to 5 g of γ-((L-valyl)oxy)butanoic acid and
the modified release component comprises 9 g to 12 g of γ-((L-valyl)oxy)butanoic acid.
13. The pharmaceutical composition of claim 8 , wherein
the immediate release component comprises 4.5 g of γ-((L-valyl)oxy)butanoic acid and
the modified release component comprises 10 g of γ-((L-valyl)oxy)butanoic acid.
14. The pharmaceutical composition of claim 1 , wherein the immediate release microparticles have an average particle diameter from 75 μm to 450 μm, wherein the average particle diameter is determined by sieve analysis.
15. The pharmaceutical composition of claim 1 , wherein
the immediate release component comprises immediate release microparticles; and
the modified release component comprises modified release microparticles.